Compare · EYE vs STAA
EYE vs STAA
Side-by-side comparison of National Vision Holdings Inc. (EYE) and STAAR Surgical Company (STAA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EYE and STAA operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- EYE is the larger of the two at $1.48B, about 1.3x STAA ($1.16B).
- STAA has been more active in the news (11 items in the past 4 weeks vs 8 for EYE).
- STAA has more recent analyst coverage (25 ratings vs 20 for EYE).
- Company
- National Vision Holdings Inc.
- STAAR Surgical Company
- Price
- -
- -
- Market cap
- $1.48B
- $1.16B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 8
- 11
- Recent ratings
- 20
- 25
National Vision Holdings Inc.
National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. As of January 2, 2021, the company operated through 1,205 retail stores, as well as various e-commerce websites. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.
STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Latest EYE
- Chief Executive Officer Wilkes Alexander converted options into 61,786 shares and covered exercise/tax liability with 29,884 shares, increasing direct ownership by 136% to 55,441 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by National Vision Holdings Inc.
- SEC Form 10-Q filed by National Vision Holdings Inc.
- National Vision Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- National Vision Holdings, Inc. Reports Second Quarter 2026 Financial Results
- Amendment: SEC Form SCHEDULE 13G/A filed by National Vision Holdings Inc.
- SEC Form SCHEDULE 13G filed by National Vision Holdings Inc.
- Chief Executive Officer Wilkes Alexander converted options into 13,768 shares and covered exercise/tax liability with 6,660 shares, increasing direct ownership by 43% to 23,539 units (SEC Form 4)
- National Vision Holdings, Inc. Announces Second Quarter 2026 Earnings Release and Conference Call
- President, America's Best Banner Mark converted options into 11,728 shares and covered exercise/tax liability with 4,964 shares, increasing direct ownership by 38% to 24,603 units (SEC Form 4)
Latest STAA
- Chief Development Officer Michna Magda exercised 6,599 shares at a strike of $4.36 and covered exercise/tax liability with 3,356 shares, increasing direct ownership by 9% to 41,343 units (SEC Form 4)
- Chief Financial Officer & EVP Andrews Deborah J converted options into 5,233 shares and covered exercise/tax liability with 2,662 shares, increasing direct ownership by 7% to 38,910 units (SEC Form 4)
- President and CEO Foust Warren converted options into 10,997 shares and covered exercise/tax liability with 5,595 shares, increasing direct ownership by 11% to 95,816 units (SEC Form 4)
- SEC Form 10-Q filed by STAAR Surgical Company
- STAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- STAAR Surgical Reports Second Quarter 2026 Results
- STAAR Surgical Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- President and CEO Foust Warren converted options into 20,787 shares and covered exercise/tax liability with 10,576 shares, increasing direct ownership by 13% to 86,556 units (SEC Form 4)
- Chief Financial Officer & EVP Andrews Deborah J converted options into 34,742 shares and covered exercise/tax liability with 17,056 shares, increasing direct ownership by 95% to 36,339 units (SEC Form 4)
- STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer